CCSG support of research nurses and clinical research associates dedicated to the conduct and completion of innovative, feasibility or proof-of-principle clinical trials proposed by Cancer Center Programs is critical for SJCRH's continued contribution to pediatric oncology. The Cancer Center leadership is dedicated to protocolspecific research and only trials considered to be of the highest priority are supported by this resource. Our commitment to protocol-based research is illustrated in Summary Table 3 in section 7.0 of this grant application. That table shows that for the index year of October 1, 2005 through September 30, 2006, of 373 patients presenting to St. Jude, 247 (66%) were treated on a therapeutic clinical trial as part of their initial treatment at St. Jude. Eighty-five (85%) of these enrollments were Cancer Center protocols, with the remaining 15% on industry or national protocols. In addition, of the 247 patients enrolling on therapeutic trials during the index year, 56 (23%) were also treated on more than one trial, resulting in 312 therapeutic enrollments. This is largely a result of St. Jude's concentrated effort to recruit previously treated patients to St. Jude for our Phase l/ll Developmental Therapeutics Program. Finally, the 373 patients presenting during the index year also contributed to 549 non-therapeutic enrollments, for a total of 861 protocol enrollments during the index year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-33
Application #
8234131
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
33
Fiscal Year
2011
Total Cost
$164,933
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
ElInati, Elias; Russell, Helen R; Ojarikre, Obah A et al. (2017) DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci U S A 114:12536-12541
Gibson, Todd M; Li, Zhenghong; Green, Daniel M et al. (2017) Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 26:1705-1713
Scott, Daniel C; Hammill, Jared T; Min, Jaeki et al. (2017) Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13:850-857
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Penkert, Rhiannon R; Jones, Bart G; H├Ącker, Hans et al. (2017) Vitamin A differentially regulates cytokine expression in respiratory epithelial and macrophage cell lines. Cytokine 91:1-5
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2017) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer :
Talleur, Aimee C; Triplett, Brandon M; Federico, Sara et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Hapl Biol Blood Marrow Transplant 23:1910-1917
Wu, Jianrong (2017) Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Stat Biopharm Res 9:25-34
Svolos, P; Reddick, W E; Edwards, A et al. (2017) Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR Am J Neuroradiol 38:1235-1241
Lin, Wenwei; Goktug, Asli N; Wu, Jing et al. (2017) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. Assay Drug Dev Technol 15:383-394

Showing the most recent 10 out of 6607 publications